Highlights

  • ResMed (ASX:RMD) shares were trading at A$30.56, down 2.71% at the time of writing on 9 September 2026.
  • The decline was steeper than the 1.69% fall in the S&P/ASX 200 Health Care index during the session.
  • ResMed reported record Q4 FY26 Revenue of approximately US$1.5 billion, while full-year revenue reached US$5.7 billion.
  • Investors are monitoring Demand across sleep and breathing health products, margins, digital healthcare expansion and Capital allocation.

ResMed Inc (ASX:RMD) shares were among the more notable healthcare decliners on Wednesday, trading at A$30.56, down 2.71% at the time of writing on 9 September 2026.

The decline occurred against a generally weaker Australian Equity market. The S&P/ASX 200 (ASX:XJO) was trading at 8,896.00 points, down 0.28% at the time of writing on 9 September 2026, while the S&P/ASX 300 (ASX:XKO) stood at 8,824.90 points, down 0.31%.

Healthcare stocks faced heavier selling pressure, with the S&P/ASX 200 Health Care (ASX:XHJ) trading at 31,299.70 points, down 1.69% at the time of writing on 9 September 2026.

ResMed’s decline was therefore larger than both the wider market and healthcare benchmark. However, without a specific catalyst attached to Wednesday’s trading, the move should not automatically be interpreted as evidence of a deterioration in the company’s fundamentals.

Sleep Health at Scale

ResMed is a global healthcare technology company focused primarily on sleep-disordered breathing, respiratory care and digital health.

Its core products include continuous positive airway pressure devices, commonly known as CPAP machines, alongside masks, accessories and cloud-connected technologies used to help diagnose, treat and manage sleep apnoea and other respiratory conditions.

The company has developed a significant ecosystem around home-based healthcare. Its devices are increasingly supported by digital platforms that connect patients, healthcare professionals and equipment providers, allowing treatment adherence and patient outcomes to be monitored remotely.

ResMed operates across more than 140 countries and positions its connected-device technology and software as part of a broader shift toward personalised and home-based healthcare.

This model gives the company exposure to long-term healthcare trends including growing recognition of sleep disorders, ageing populations, increasing healthcare digitisation and demand for treatment outside traditional hospital settings.

FY26 Sets the Benchmark

ResMed released its fourth-quarter and full-year FY26 results on 6 August 2026, providing investors with a recent detailed view of the company’s financial performance.

Fourth-quarter revenue increased 9% to approximately US$1.5 billion, or 8% on a constant-currency basis. Management said demand was evident across sleep devices, masks, accessories and software solutions.

For the full financial year ended 30 June 2026, revenue increased 10% to US$5.7 billion, with constant-currency growth of 8%.

Profitability also improved. ResMed reported a FY26 GAAP gross Margin of 61.1%, up 170 basis points, while its non-GAAP gross margin expanded 240 basis points to 62.4%. GAAP Operating Margin reached 33.4%, while the non-GAAP operating margin was 36.1%.

Full-year GAAP Diluted Earnings per Share were US$10.43, while non-GAAP diluted EPS reached US$11.17, representing growth of 17%.

Cash generation remained another important feature. FY26 Operating Cash Flow reached US$1.8 billion, while free cash flow totalled US$1.6 billion.

The August results therefore provide investors with a broader fundamental backdrop against which to assess short-term movements in ResMed’s share price.

Products, Portfolio and Capital

ResMed continued to expand its product offering during FY26.

The company highlighted launches across different international markets, including AirSense 11 in Taiwan, AirCurve 11 ST/ST-A in the United States and AirTouch F30i Comfort in Brazil and Chile.

Portfolio management is another area attracting attention. ResMed announced an agreement in July to sell its MatrixCare business, while it completed the Acquisition of Noctrix Health in June. Noctrix adds a wearable therapeutic designed for restless legs syndrome to ResMed’s broader sleep-health portfolio.

Capital returns are also significant. ResMed returned approximately US$1.0 billion to shareholders through share repurchases and dividends during FY26. For FY27, management said it was guiding toward returning more than US$1.85 billion through Buybacks and dividends and announced a 10% increase in the quarterly Dividend to US$0.66 per share.

These decisions highlight the balance ResMed is seeking between Investment in innovation, strategic portfolio changes and returns to shareholders.

What Investors Are Watching

For ResMed, future investor attention is likely to centre on several areas.

The first is continued demand for sleep apnoea treatment. Sleep-disordered breathing remains an underdiagnosed condition globally, giving ResMed a potentially substantial addressable market. Maintaining device adoption and increasing patient engagement are therefore central to the growth story.

Margins are another important consideration. ResMed’s FY26 improvement in gross and operating margins reflected increased operating efficiency, but investors are likely to watch whether further revenue growth can continue translating into profitable expansion.

Digital health is also becoming increasingly relevant. ResMed’s connected devices and software give the company exposure beyond traditional medical-device manufacturing, with data and digital capabilities potentially strengthening patient adherence and healthcare-provider engagement.

Competition, reimbursement policies, regulatory requirements, product innovation and healthcare spending patterns are additional variables that can influence performance.

Valuation also matters. When healthcare technology companies establish high growth expectations, share prices can become sensitive to relatively small changes in expectations for revenue, margins or earnings. That means a sharp daily movement can reflect shifting investor expectations without necessarily signalling a corresponding change in underlying operations.

Final Takeaway

ResMed (ASX:RMD) shares were trading at A$30.56, down 2.71% at the time of writing on 9 September 2026, compared with a 1.69% decline in the S&P/ASX 200 Health Care Index.

The size of the decline makes ResMed one of the more notable healthcare movers in the session, but the price action should be considered separately from the company’s underlying Business performance unless a specific catalyst is established.

ResMed’s August FY26 results showed record quarterly revenue, full-year revenue of US$5.7 billion, expanding margins and US$1.6 billion in free cash flow.

Looking beyond one trading day, investors are likely to remain focused on sleep-device demand, product innovation, digital-health adoption, margin development, portfolio execution and capital allocation as ResMed progresses through FY27.